GOSS — Gossamer Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1728117 ·
Last close
$0.22
Market Cap
$51.63M
52W High
$0.60
52W Low
$0.16
ADV30
9,193,082
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 16,955,000 | — | -44,866,000 | -46,664,000 | 128,899,000 | 41,028,000 | 290,382,000 |
| Dec 2025 | 13,799,000 | — | -46,040,000 | -47,238,000 | 172,249,000 | 37,732,000 | 295,009,000 |
| Sep 2025 | 13,294,000 | — | -41,638,000 | -48,221,000 | 208,820,000 | 8,933,000 | 291,153,000 |
| Jun 2025 | 11,489,000 | — | -38,765,000 | -38,273,000 | 240,925,000 | 26,309,000 | 287,032,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-171,266,000
Investing CF
$156,358,000
Financing CF
$6,425,000
CapEx
$-79,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.75
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,438,938,000
Inventory
—
Receivables
$12,227,000
ST Investments
$99,200,000
EBIT TTM
$-159,469,000
Pretax Income TTM
$-170,458,000
Interest Exp TTM
$10,989,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$55,537,000
EBITDA
$-171,286,000
Free Cash Flow
$-97,250,872
Enterprise Value
$153,027,696
Total Cash
$99,215,000
Total Debt
$202,932,992
Shares Out
234,696,281
Trailing EPS
$-0.79
Book Value
$-0.69
ROE
—
ROA
-52.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,471,000 | -163,253,000 | -170,370,000 | 172,249,000 | 295,009,000 | — | -171,266,000 |
| Dec 2024 | 114,701,000 | -59,919,000 | -56,528,000 | 315,292,000 | 285,800,000 | — | -3,468,000 |
| Dec 2023 | 0 | -173,759,000 | -179,817,000 | 311,916,000 | 249,147,000 | — | -159,158,000 |
| Dec 2022 | 0 | -218,528,000 | -229,378,000 | 272,450,000 | 260,373,000 | — | -187,032,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$10,136,000
NetIncome TTM
$-190,421,000
OpCashFlow TTM
$0
Assets (Latest)
$315,292,000
Forward EPS
$-0.11
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QUCY | Quantum Cyber N.V. | $50.87M | $3.47 | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $52.64M | $2.20 | — |
| MREO | Mereo BioPharma Group plc | $53.26M | $0.33 | — |
| XLO | Xilio Therapeutics, Inc. | $49.96M | $8.35 | — |
| INCR | Intercure Ltd. | $49.51M | $0.91 | — |
News headlines (Yahoo Finance, 1h cache)
Pulmonary Arterial Hypertension Market Outlook Shows Strong Upward Trend at a CAGR of 6.7% During the Study Period (2022-2036) Supported by New Clinical Developments | DelveInsight
2026-05-25 21:31 · Yahoo
Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS)
2026-05-18 14:14 · Yahoo
Gossamer Bio Q1 Earnings Call Highlights
2026-05-18 13:05 · Yahoo
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
2026-05-18 11:05 · Yahoo
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-18 11:00 · Yahoo
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
2026-05-15 23:30 · Yahoo
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
2026-05-15 11:01 · Yahoo
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-14 12:30 · Yahoo
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
2026-05-12 21:15 · Yahoo
How The Gossamer Bio (GOSS) Story Is Shifting After The PROSERA Miss And Cash Concerns
2026-05-11 20:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.